RECRUITINGOBSERVATIONAL
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)
About This Trial
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
Who May Be Eligible (Plain English)
Who May Qualify:
- The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
- The subject or their legal representative agrees to participate in this study and signs a written ICF.
- The subjects are willing and able to follow planned visits and procedures.
Who Should NOT Join This Trial:
- None
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
* The subject or their legal representative agrees to participate in this study and signs a written ICF.
* The subjects are willing and able to follow planned visits and procedures.
Exclusion Criteria:
* None
Locations (1)
Chinese Academy of Medical Sciences & Peking Union Hospital
Beijing, Beijing Municipality, China